Cover Image
市場調查報告書

全球免疫學市場:大規模開發平台和競爭市場促進長期性的市場成長

Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

出版商 GBI Research 商品編碼 350752
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
全球免疫學市場:大規模開發平台和競爭市場促進長期性的市場成長 Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
出版日期: 2015年12月01日 內容資訊: 英文 133 Pages
簡介

全球免疫學市場的收益從2015年的615億美元,2022年增加到742億美元,預計以2.71%的年複合成長率成長。

本報告提供全球免疫學市場相關調查分析,市場概要,上市產品,開發中產品,市場預測,交易與策略性整合等系統性資訊

第1章 目錄

第2章 簡介

  • 治療領域的介紹
  • 症狀
  • 病因與病情生理
  • 合併症和併發症
  • 流行病學模式與預測
  • 治療

第3章 主要上市產品

  • 概要
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Enbrel (etanercept)
  • Rituxan (rituximab)
  • Stelara (ustekinumab)
  • Prograf (tacrolimus)
  • Cimzia (certolizumab pegol)
  • Simponi (golimumab)
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台開發形勢
  • 開發平台的分子標的
  • 臨床試驗
  • 結論

第5章 多方案的市場預測

  • 市場規模全體
  • 非專利的普及
  • 收益預測:各分子標的

第6章 企業分析與定位

  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC376MR

Executive Summary

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5-7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Scope

Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.

  • What factors are driving the market growth?
  • How can the factors limiting growth be overcome?

There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.

  • What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
  • How does the composition of the pipeline compare with that of the existing market?

Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.

  • How will this affect their revenues in this period?
  • How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?

The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.

  • What is driving this continued market dominance?
  • Who will the new market players be?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
  • Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
  • 2.4. Co-morbidities and Complications
  • 2.5. Epidemiology Patterns and Forecasts - Prevalence, Patient Segmentation, Diagnostic and Treatment Usage Rates
    • 2.5.1. Rheumatoid Arthritis
    • 2.5.2. Psoriasis
    • 2.5.3. Systemic Lupus Erythematosus
  • 2.6. Treatment
    • 2.6.1. Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
    • 2.6.2. Glucocorticoids
    • 2.6.3. Biologics

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Humira (adalimumab)
  • 3.3. Remicade (infliximab)
  • 3.4. Enbrel (etanercept)
  • 3.5. Rituxan (rituximab)
  • 3.6. Stelara (ustekinumab)
  • 3.7. Prograf (tacrolimus)
  • 3.8. Cimzia (certolizumab pegol)
  • 3.9. Simponi (golimumab)
  • 3.10. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
  • 4.5. Conclusion

5. Multi-Scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Tumor Necrosis Factor-Alpha
    • 5.3.2. Interleukin-6 and Interleukin-6 Receptor
    • 5.3.3. Interleukins-1, 2, 5, 12, 17 and 23 and Receptors
    • 5.3.4. Janus Kinases
    • 5.3.5. Revenue and Market Share Analysis by Company
    • 5.3.6. Assessment of Key Pipeline Products

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Immunology, Global, Epidemiology of Inflammatory Immunological Disorders, 2015
  • Table 2: Immunology Therapeutics Market, Global, Approved Indications for Humira, 2015
  • Table 3: Immunology Therapeutics Market, Global, Approved Indications for Remicade, 2015
  • Table 4: Immunology Therapeutics Market, Global, Approved Indications for Enbrel, 2015
  • Table 5: Immunology Therapeutics Market, Global, Approved Indications for Rituxan, 2015
  • Table 6: Immunology Therapeutics Market, Global, Approved Indications for Stelara, 2015
  • Table 7: Immunology Therapeutics Market, Global, Approved Indications for Prograf, 2015
  • Table 8: Immunology Therapeutics Market, Global, Approved Indications for Cimzia, 2015
  • Table 9: Immunology Therapeutics Market, Global, Approved Indications for Simponi, 2015
  • Table 10: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2014-2022
  • Table 11: Immunology, Global, Usage of Generics Across Key Indications, 2015
  • Table 12: Immunology Therapeutics Market, Global, Forecast Revenues by Company, 2014-2022
  • Table 13: Immunology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2015
  • Table 14: Immunology Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006-2015
  • Table 15: Immunology, Global, Table of all Clinical Stage Pipeline Products, 2015

List of Figures

  • Figure 1: Immunology, Global, Epidemiology Patterns for Rheumatoid Arthritis (million), 2015-2022
  • Figure 2: Immunology, Global, Epidemiology Patterns for Psoriasis, Patients (million), 2015-2022
  • Figure 3: Immunology, Global, Epidemiology for Systemic Lupus Erythematosus ('000), 2015-2022
  • Figure 4: Immunology, Global, Key Marketed Products and Approved Indications, 2015
  • Figure 5: Immunology Therapeutics Market, Global, Annual Revenues for Humira ($bn), 2006-2022
  • Figure 6: Immunology Therapeutics Market, Global, Annual Revenues for Remicade ($bn), 2006-2022
  • Figure 7: Immunology Therapeutics Market, Global, Annual Revenues for Enbrel ($bn), 2006-2022
  • Figure 8: Immunology Therapeutics Market, Global, Annual Revenues for Rituxan ($bn), 2006-2022
  • Figure 9: Immunology Therapeutics Market, Global, Annual Revenues for Stelara ($bn), 2010-2022
  • Figure 10: Immunology Therapeutics Market, Global, Annual Revenues for Prograf ($bn), 2006-2022
  • Figure 11: Immunology Therapeutics Market, Global, Annual Revenues for Cimzia ($bn), 2006-2022
  • Figure 12: Immunology Therapeutics Market, Global, Annual Revenues for Simponi ($bn), 2006-2022
  • Figure 13: Immunology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2015
  • Figure 14: Immunology Therapeutics Market, Global, Pipeline for Immunology by Stage of Development, Molecule Type and Program Type, 2015
  • Figure 15: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2015
  • Figure 16: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2015
  • Figure 17: Immunology Therapeutics Market, Global, Pipeline for Immunology by Molecular Target, 2015
  • Figure 18: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2015
  • Figure 19: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2015
  • Figure 20: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2015
  • Figure 21: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2015
  • Figure 22: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2015
  • Figure 23: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2015
  • Figure 24: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2015
  • Figure 25: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2015
  • Figure 26: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2015
  • Figure 27: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2015
  • Figure 28: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015
  • Figure 29: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2015
  • Figure 30: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2015
  • Figure 31: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2015
  • Figure 32: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2015
  • Figure 33: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015
  • Figure 34: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2015
  • Figure 35: Immunology, Global, Market Size ($m), 2015-2022
  • Figure 36: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2014-2022
  • Figure 37: Immunology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2014-2022
  • Figure 38: Immunology, Global, Annual Revenue Forecast for Interleukin-6 Inhibitors ($bn), 2014-2022
  • Figure 39: Immunology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
  • Figure 40: Immunology, Global, Annual Revenue Forecast for Janus Kinase Inhibitors ($bn), 2014-2022
  • Figure 41: Immunology Therapeutics Market, Global, Forecast Market Share by Company (%), 2014-2022
  • Figure 42: Immunology, Global, Companies by Compound Annual Growth Rate (%), 2014-2022
  • Figure 43: Immunology, Global, Revenues by Product Type, 2014-2022
  • Figure 44: Immunology, Global, AbbVie Annual Revenue Forecast ($bn), 2014-2022
  • Figure 45: Immunology, Global, Johnson & Johnson Annual Revenue Forecast ($m), 2014-2022
  • Figure 46: Immunology, Global, Roche Annual Revenue Forecast ($m), 2014-2022
  • Figure 47: Immunology, Global, Amgen Annual Revenue Forecast ($m), 2014-2022
  • Figure 48: Immunology, Global, Novartis Annual Revenue Forecast ($m), 2014-2022
  • Figure 49: Immunology Therapeutics Market, Global, Revenue Forecast for baricitinib ($m), 2015-2022
  • Figure 50: Immunology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015-2022
  • Figure 51: Immunology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2015-2022
  • Figure 52: Immunology Therapeutics Market, Global, Revenue Forecast for sarilumab ($m), 2015-2022
  • Figure 53: Immunology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2015-2022
  • Figure 54: Immunology, Global, Companies by Type, 2015
  • Figure 55: Immunology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Immunology Specialization, 2015
  • Figure 56: Immunology, Global, Proportion of Total Company Revenue Attributed to Immunology, 2014-2022
  • Figure 57: Immunology, Global, Licensing Deals, 2006-2015
  • Figure 58: Immunology, Global, Licensing Deals by Indication and Value, 2006-2015
  • Figure 59: Immunology, Global, Licensing Deals, 2006-2015
  • Figure 60: Immunology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2015
  • Figure 61: Immunology, Global, Co-development Deals, 2006-2015
  • Figure 62: Immunology, Global, Co-development Deals by Indication and Value, 2006-2015
  • Figure 63: Immunology, Global, Co-development Deals, 2006-2015
  • Figure 64: Immunology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2015
Back to Top